Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state

  1. Yarden Katz
  2. Feifei Li
  3. Nicole J Lambert
  4. Ethan S Sokol
  5. Wai Leong Tam
  6. Albert W Cheng
  7. Edoardo M Airoldi
  8. Christopher J Lengner
  9. Piyush B Gupta
  10. Zhengquan Yu
  11. Rudolf Jaenisch
  12. Christopher B Burge  Is a corresponding author
  1. Massachusetts Institute of Technology, United States
  2. China Agricultural University, China
  3. Whitehead Institute for Biomedical Research, United States
  4. Harvard University, United States
  5. University of Pennsylvania, United States

Abstract

The conserved Musashi (Msi) family of RNA binding proteins are expressed in stem/progenitor and cancer cells, but generally absent from differentiated cells, consistent with a role in cell state regulation. We found that Msi genes are rarely mutated but frequently overexpressed in human cancers, and are associated with an epithelial-luminal cell state. Using ribosome profiling and RNA-seq analysis of genetic mouse models in neuronal and mammary cell types, we found that Msis regulate translation of genes implicated in epithelial cell biology and epithelial-to-mesenchymal transition (EMT) and promote an epithelial splicing pattern. Overexpression of Msi proteins inhibited translation of genes required for EMT, including Jagged1, and repressed EMT in cell culture and in mammary gland in vivo, while knockdown in epithelial cancer cells promoted loss of epithelial identity. Our results show that mammalian Msi proteins contribute to an epithelial gene expression program in neural and mammary cell types.

Article and author information

Author details

  1. Yarden Katz

    Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    No competing interests declared.
  2. Feifei Li

    China Agricultural University, Beijing, China
    Competing interests
    No competing interests declared.
  3. Nicole J Lambert

    Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    No competing interests declared.
  4. Ethan S Sokol

    Whitehead Institute for Biomedical Research, Cambridge, United States
    Competing interests
    No competing interests declared.
  5. Wai Leong Tam

    Whitehead Institute for Biomedical Research, Cambridge, United States
    Competing interests
    No competing interests declared.
  6. Albert W Cheng

    Whitehead Institute for Biomedical Research, Cambridge, United States
    Competing interests
    No competing interests declared.
  7. Edoardo M Airoldi

    Harvard University, Cambridge, United States
    Competing interests
    Edoardo M Airoldi, Reviewing Editor, eLife.
  8. Christopher J Lengner

    University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  9. Piyush B Gupta

    Whitehead Institute for Biomedical Research, Cambridge, United States
    Competing interests
    No competing interests declared.
  10. Zhengquan Yu

    China Agricultural University, Beijing, China
    Competing interests
    No competing interests declared.
  11. Rudolf Jaenisch

    Whitehead Institute for Biomedical Research, Cambridge, United States
    Competing interests
    No competing interests declared.
  12. Christopher B Burge

    Massachusetts Institute of Technology, Cambridge, United States
    For correspondence
    cburge@mit.edu
    Competing interests
    No competing interests declared.

Reviewing Editor

  1. Benjamin J Blencowe, University of Toronto, Canada

Ethics

Animal experimentation: Mice of the 129SvJae strain were used, and the K14-rTTA strain were obtained from JAX (stock number: 007678). Animal care was performed in accordance with institutional guidelines and approved by the Committee on Animal Care, Department of Comparative Medicine, Massachusetts Institute of Technology, under animal protocol 1013-088-16

Version history

  1. Received: July 6, 2014
  2. Accepted: November 5, 2014
  3. Accepted Manuscript published: November 7, 2014 (version 1)
  4. Version of Record published: December 15, 2014 (version 2)

Copyright

© 2014, Katz et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,994
    views
  • 650
    downloads
  • 78
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yarden Katz
  2. Feifei Li
  3. Nicole J Lambert
  4. Ethan S Sokol
  5. Wai Leong Tam
  6. Albert W Cheng
  7. Edoardo M Airoldi
  8. Christopher J Lengner
  9. Piyush B Gupta
  10. Zhengquan Yu
  11. Rudolf Jaenisch
  12. Christopher B Burge
(2014)
Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state
eLife 3:e03915.
https://doi.org/10.7554/eLife.03915

Share this article

https://doi.org/10.7554/eLife.03915

Further reading

    1. Cancer Biology
    2. Cell Biology
    Timothy J Walker, Eduardo Reyes-Alvarez ... Lois M Mulligan
    Research Article

    Internalization from the cell membrane and endosomal trafficking of receptor tyrosine kinases (RTKs) are important regulators of signaling in normal cells that can frequently be disrupted in cancer. The adrenal tumor pheochromocytoma (PCC) can be caused by activating mutations of the rearranged during transfection (RET) receptor tyrosine kinase, or inactivation of TMEM127, a transmembrane tumor suppressor implicated in trafficking of endosomal cargos. However, the role of aberrant receptor trafficking in PCC is not well understood. Here, we show that loss of TMEM127 causes wildtype RET protein accumulation on the cell surface, where increased receptor density facilitates constitutive ligand-independent activity and downstream signaling, driving cell proliferation. Loss of TMEM127 altered normal cell membrane organization and recruitment and stabilization of membrane protein complexes, impaired assembly, and maturation of clathrin-coated pits, and reduced internalization and degradation of cell surface RET. In addition to RTKs, TMEM127 depletion also promoted surface accumulation of several other transmembrane proteins, suggesting it may cause global defects in surface protein activity and function. Together, our data identify TMEM127 as an important determinant of membrane organization including membrane protein diffusability and protein complex assembly and provide a novel paradigm for oncogenesis in PCC where altered membrane dynamics promotes cell surface accumulation and constitutive activity of growth factor receptors to drive aberrant signaling and promote transformation.

    1. Cancer Biology
    2. Genetics and Genomics
    Ting Zhang, Alisa Ambrodji ... Steven M Offer
    Research Article

    Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome-edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.